September 2019 Issue Table Of Contents

From The Editor

• Oh, The Misperceptions We Hold

Feature Article

• The Story Of Pfizer’s R&D Turnaround
• What’s Necessary To Realize The Promise Of Digital Health Solutions?

Capitol Perspectives

• Republicans … Insert Price Controls In Part D

CEO Corner

• My Advice To Aspiring Biopharma Entrepreneurs

From Principles and Policy to Execution

• A Patient In Need Of Resuscitation — A Tale Of Different Healthcare Systems

Companies To Watch

• Leading Biosciences

Industry Research

• What To Prioritize When Selecting A Phase 1 CRO

Inside The Industry

• Patient Diversity Starts With Community Connections
• Athira’s Whole-Patient Drug Development
• Comparative Biosimilar Clinical Trials: More Questions Than Answers?
• Culturing The Culture
• Jeremy Levin Weighs In On Biosimilar Patent Thicket

Leadership Lessons

• 3 Ways Leaders Can Help Employees Prepare For The Future

Ask The Board

• What Are The Critical Components Necessary When Attempting To Attract An Angel Investor To Your Biopharmaceutical Startup?
• What Should Be Done By Engineers Toward Developing New Methods And Approaches For Process Development And Facility Design To Make The Wide Range Of New Products Faster And Cheaper?
• What Are The Critical Components Necessary When Attempting To Attract An Angel Investor To Your Biopharma Startup?